Cancer- and chemotherapy-induced anemia: Clinical practice guidelines in oncology

George M. Rodgers, Pamela Sue Becker, Morey Blinder, David Cella, Asher A Chanan Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic, Alva B. Weir

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer- and Chemotherapy-Induced Anemia underwent substantial revisions this year. The purpose of these NCCN Guidelines is twofold: 1) to operationalize the evaluation and treatment of anemia in adult cancer patients, with an emphasis on those who are receiving concomitant chemotherapy, and 2) to enable patients and clinicians to individualize anemia treatment options based on patient condition.

Original languageEnglish (US)
Pages (from-to)628-653
Number of pages26
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume10
Issue number5
StatePublished - May 1 2012
Externally publishedYes

Fingerprint

Practice Guidelines
Anemia
Drug Therapy
Hematinics
Neoplasms
Guidelines
Iron
Erythrocytes
Health
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Rodgers, G. M., Becker, P. S., Blinder, M., Cella, D., Chanan Khan, A. A., Cleeland, C., ... Weir, A. B. (2012). Cancer- and chemotherapy-induced anemia: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 10(5), 628-653.

Cancer- and chemotherapy-induced anemia : Clinical practice guidelines in oncology. / Rodgers, George M.; Becker, Pamela Sue; Blinder, Morey; Cella, David; Chanan Khan, Asher A; Cleeland, Charles; Coccia, Peter F.; Djulbegovic, Benjamin; Gilreath, Jeffrey A.; Kraut, Eric H.; Matulonis, Ursula A.; Millenson, Michael M.; Reinke, Denise; Rosenthal, Joseph; Schwartz, Rowena N.; Soff, Gerald; Stein, Richard S.; Vlahovic, Gordana; Weir, Alva B.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 10, No. 5, 01.05.2012, p. 628-653.

Research output: Contribution to journalArticle

Rodgers, GM, Becker, PS, Blinder, M, Cella, D, Chanan Khan, AA, Cleeland, C, Coccia, PF, Djulbegovic, B, Gilreath, JA, Kraut, EH, Matulonis, UA, Millenson, MM, Reinke, D, Rosenthal, J, Schwartz, RN, Soff, G, Stein, RS, Vlahovic, G & Weir, AB 2012, 'Cancer- and chemotherapy-induced anemia: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 5, pp. 628-653.
Rodgers, George M. ; Becker, Pamela Sue ; Blinder, Morey ; Cella, David ; Chanan Khan, Asher A ; Cleeland, Charles ; Coccia, Peter F. ; Djulbegovic, Benjamin ; Gilreath, Jeffrey A. ; Kraut, Eric H. ; Matulonis, Ursula A. ; Millenson, Michael M. ; Reinke, Denise ; Rosenthal, Joseph ; Schwartz, Rowena N. ; Soff, Gerald ; Stein, Richard S. ; Vlahovic, Gordana ; Weir, Alva B. / Cancer- and chemotherapy-induced anemia : Clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2012 ; Vol. 10, No. 5. pp. 628-653.
@article{f31a1e9adf2c4eb5bf12e690f5aaa145,
title = "Cancer- and chemotherapy-induced anemia: Clinical practice guidelines in oncology",
abstract = "Anemia is prevalent in 30{\%} to 90{\%} of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer- and Chemotherapy-Induced Anemia underwent substantial revisions this year. The purpose of these NCCN Guidelines is twofold: 1) to operationalize the evaluation and treatment of anemia in adult cancer patients, with an emphasis on those who are receiving concomitant chemotherapy, and 2) to enable patients and clinicians to individualize anemia treatment options based on patient condition.",
author = "Rodgers, {George M.} and Becker, {Pamela Sue} and Morey Blinder and David Cella and {Chanan Khan}, {Asher A} and Charles Cleeland and Coccia, {Peter F.} and Benjamin Djulbegovic and Gilreath, {Jeffrey A.} and Kraut, {Eric H.} and Matulonis, {Ursula A.} and Millenson, {Michael M.} and Denise Reinke and Joseph Rosenthal and Schwartz, {Rowena N.} and Gerald Soff and Stein, {Richard S.} and Gordana Vlahovic and Weir, {Alva B.}",
year = "2012",
month = "5",
day = "1",
language = "English (US)",
volume = "10",
pages = "628--653",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - Cancer- and chemotherapy-induced anemia

T2 - Clinical practice guidelines in oncology

AU - Rodgers, George M.

AU - Becker, Pamela Sue

AU - Blinder, Morey

AU - Cella, David

AU - Chanan Khan, Asher A

AU - Cleeland, Charles

AU - Coccia, Peter F.

AU - Djulbegovic, Benjamin

AU - Gilreath, Jeffrey A.

AU - Kraut, Eric H.

AU - Matulonis, Ursula A.

AU - Millenson, Michael M.

AU - Reinke, Denise

AU - Rosenthal, Joseph

AU - Schwartz, Rowena N.

AU - Soff, Gerald

AU - Stein, Richard S.

AU - Vlahovic, Gordana

AU - Weir, Alva B.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer- and Chemotherapy-Induced Anemia underwent substantial revisions this year. The purpose of these NCCN Guidelines is twofold: 1) to operationalize the evaluation and treatment of anemia in adult cancer patients, with an emphasis on those who are receiving concomitant chemotherapy, and 2) to enable patients and clinicians to individualize anemia treatment options based on patient condition.

AB - Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer- and Chemotherapy-Induced Anemia underwent substantial revisions this year. The purpose of these NCCN Guidelines is twofold: 1) to operationalize the evaluation and treatment of anemia in adult cancer patients, with an emphasis on those who are receiving concomitant chemotherapy, and 2) to enable patients and clinicians to individualize anemia treatment options based on patient condition.

UR - http://www.scopus.com/inward/record.url?scp=84861818190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861818190&partnerID=8YFLogxK

M3 - Article

C2 - 22570293

AN - SCOPUS:84861818190

VL - 10

SP - 628

EP - 653

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 5

ER -